JP2020503345A - 肺におけるインフラマソーム活性及び炎症をモジュレートする方法 - Google Patents

肺におけるインフラマソーム活性及び炎症をモジュレートする方法 Download PDF

Info

Publication number
JP2020503345A
JP2020503345A JP2019536086A JP2019536086A JP2020503345A JP 2020503345 A JP2020503345 A JP 2020503345A JP 2019536086 A JP2019536086 A JP 2019536086A JP 2019536086 A JP2019536086 A JP 2019536086A JP 2020503345 A JP2020503345 A JP 2020503345A
Authority
JP
Japan
Prior art keywords
antibody
inflammasome
asc
lung
aim2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019536086A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020503345A5 (cg-RX-API-DMAC7.html
Inventor
キーン，ロバート
ディートリヒ，ダルトン
カー，ナディーン
ウー，シュー
リベロ ヴァッカリ，ジュアン パブロ デ
リベロ ヴァッカリ，ジュアン パブロ デ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Miami
Original Assignee
University of Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Miami filed Critical University of Miami
Publication of JP2020503345A publication Critical patent/JP2020503345A/ja
Publication of JP2020503345A5 publication Critical patent/JP2020503345A5/ja
Priority to JP2022181180A priority Critical patent/JP2023016835A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019536086A 2016-12-29 2017-12-28 肺におけるインフラマソーム活性及び炎症をモジュレートする方法 Pending JP2020503345A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022181180A JP2023016835A (ja) 2016-12-29 2022-11-11 肺におけるインフラマソーム活性及び炎症をモジュレートする方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662440180P 2016-12-29 2016-12-29
US62/440,180 2016-12-29
PCT/US2017/068713 WO2018126009A1 (en) 2016-12-29 2017-12-28 Method for modulating inflammasome activity and inflammation in the lung

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022181180A Division JP2023016835A (ja) 2016-12-29 2022-11-11 肺におけるインフラマソーム活性及び炎症をモジュレートする方法

Publications (2)

Publication Number Publication Date
JP2020503345A true JP2020503345A (ja) 2020-01-30
JP2020503345A5 JP2020503345A5 (cg-RX-API-DMAC7.html) 2021-02-12

Family

ID=62710025

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019536086A Pending JP2020503345A (ja) 2016-12-29 2017-12-28 肺におけるインフラマソーム活性及び炎症をモジュレートする方法
JP2022564482A Pending JP2023515271A (ja) 2016-12-29 2021-04-23 ウイルス関連炎症を処置するための方法及び組成物
JP2022181180A Pending JP2023016835A (ja) 2016-12-29 2022-11-11 肺におけるインフラマソーム活性及び炎症をモジュレートする方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022564482A Pending JP2023515271A (ja) 2016-12-29 2021-04-23 ウイルス関連炎症を処置するための方法及び組成物
JP2022181180A Pending JP2023016835A (ja) 2016-12-29 2022-11-11 肺におけるインフラマソーム活性及び炎症をモジュレートする方法

Country Status (16)

Country Link
US (5) US20190336598A1 (cg-RX-API-DMAC7.html)
EP (2) EP3562506A4 (cg-RX-API-DMAC7.html)
JP (3) JP2020503345A (cg-RX-API-DMAC7.html)
KR (1) KR20200013630A (cg-RX-API-DMAC7.html)
CN (1) CN110461356A (cg-RX-API-DMAC7.html)
AU (1) AU2017386550A1 (cg-RX-API-DMAC7.html)
BR (1) BR112019013463A2 (cg-RX-API-DMAC7.html)
CA (2) CA3048864A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019008087A2 (cg-RX-API-DMAC7.html)
IL (1) IL267685A (cg-RX-API-DMAC7.html)
MX (1) MX2019007916A (cg-RX-API-DMAC7.html)
PH (1) PH12019501549A1 (cg-RX-API-DMAC7.html)
RU (1) RU2019123160A (cg-RX-API-DMAC7.html)
SG (1) SG10202106385XA (cg-RX-API-DMAC7.html)
WO (2) WO2018126009A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201904861B (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11840565B2 (en) 2016-12-29 2023-12-12 University Of Miami Methods and compositions for treating virus-associated inflammation
US20190336598A1 (en) 2016-12-29 2019-11-07 University Of Miami Methods for modulating inflammasome activity and inflammation in the lung
KR20210071944A (ko) * 2018-07-03 2021-06-16 더 유니버시티 오브 마이애미 인플라마솜 관련 질환 또는 상태 치료용 조성물 및 방법
US20220334127A1 (en) * 2019-03-13 2022-10-20 Fundación Para La Formación E Investigación Sanitarias De La Región De Murcia (Ffis) In vitro method for obtaining clinical data in patients suffering from an inflammatory disease
WO2021097084A1 (en) * 2019-11-12 2021-05-20 The Uab Research Foundation Methods for treating immunosuppression and diseases associated with immunosuppression
CN111363847B (zh) * 2020-02-12 2021-06-29 广州微远医疗器械有限公司 基于CRISPR技术的2019-nCoV快速检测引物组及其用途
CN113278730B (zh) * 2020-02-20 2022-03-25 中元汇吉生物技术股份有限公司 一种新型冠状病毒检测试剂盒、用途及其使用方法
CN121177307A (zh) * 2020-03-19 2025-12-23 南洋理工大学 包含nlrp1炎性体激活抑制剂的化合物或组合物用于治疗人气道炎症的用途
CN111289745A (zh) * 2020-03-25 2020-06-16 中山生物工程有限公司 新型冠状病毒IgM抗体酶联免疫检测试剂盒及其检测方法
KR102658146B1 (ko) * 2020-03-26 2024-04-18 경북대학교 산학협력단 Pannexin3을 포함하는 근육 손상 진단용 바이오마커 조성물 및 이를 이용한 진단방법
US20230296626A1 (en) * 2020-04-27 2023-09-21 University Of Miami Compositions and methods for treating inflammasome related diseases or conditions
CN111529707B (zh) * 2020-04-29 2021-04-23 威海市立医院 Gsdmd抑制剂在制备治疗幽门螺杆菌感染的药物中的应用
CN111777684A (zh) * 2020-06-09 2020-10-16 重庆君同生物技术有限公司 冠状病毒串联表位蛋白所诱导抗体的制备方法及其应用
EP4179069A4 (en) * 2020-07-09 2024-10-02 Remedy Cell Ltd. METHODS FOR THE TREATMENT OF ACUTE RESPIRATORY INFLAMMATION AND CYTOKINE STORM SYNDROME
KR102582417B1 (ko) * 2020-11-06 2023-09-26 한국과학기술원 인플라마솜 어댑터 단백질(asc)의 중합체화 도메인에 결합하는 신규한 폴리펩타이드 및 이의 용도
KR102549520B1 (ko) 2021-01-29 2023-07-03 일리미스테라퓨틱스 주식회사 비염증성 식세포작용 유도 활성을 갖는 융합분자
CN113109569B (zh) * 2021-03-05 2022-08-19 李朴 Gsdmd作为生物标志物在胸腔积液相关疾病鉴别诊断及疗效评估上的用途
KR102673132B1 (ko) * 2021-04-20 2024-06-12 아주대학교산학협력단 염증성 질환 치료를 위한 nlrp3 인플라마좀 억제 펩타이드
WO2022240757A1 (en) 2021-05-10 2022-11-17 Entrada Therapeutics, Inc. Antigen-binding and antigen degradation constructs
CN118119644A (zh) * 2021-08-25 2024-05-31 R.P.谢勒技术有限责任公司 具有人源化框架区的抗体
CN115819548B (zh) * 2021-11-16 2023-09-01 北京美德泰康生物科技有限公司 一种检测炎症相关疾病的标志物和方法
WO2024006457A1 (en) * 2022-06-29 2024-01-04 University Of South Florida Method of treating long-covid induced neurologic diseases
WO2024114906A1 (en) 2022-11-30 2024-06-06 Mabylon Ag Antibodies against apoptosis-associated speck-like protein containing a card (asc) and uses thereof
WO2024248287A1 (ko) * 2023-06-01 2024-12-05 한양대학교 에리카산학협력단 결핵균 유래 폴리펩타이드를 포함하는 염증성 질환 치료용 약학 조성물
WO2025081130A1 (en) * 2023-10-12 2025-04-17 University Of Miami Use of anti-asc antibody in the treating of ocular disorders

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040018194A1 (en) 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
KR101194446B1 (ko) 2004-04-29 2012-10-24 오쓰까 세이야꾸 가부시키가이샤 당단백 ｖｉ에 특이적인 항체 및 그의 제조방법
EP1812062B1 (en) 2004-10-25 2022-03-09 Merck Sharp & Dohme Corp. Anti-addl antibodies and uses thereof
TW200636064A (en) 2004-10-28 2006-10-16 Centocor Inc Anti-respiratory syncytial virus antibodies, antigens and uses thereof
MX2009009194A (es) 2007-02-27 2009-10-08 Genentech Inc Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes.
WO2009014863A2 (en) * 2007-06-29 2009-01-29 Thomas Jefferson University Asc and pyrin-asc pyroptosomes and uses thereof
US8685400B2 (en) 2007-07-30 2014-04-01 University Of Miami Modulating inflammasome activity and inflammation in the central nervous system
US20100150938A1 (en) * 2008-07-03 2010-06-17 University Of Massachusetts Methods and compositions for reducing inflammation and treating inflammatory disorders
US20120288474A1 (en) * 2009-11-06 2012-11-15 Protaffin Biotechnologie Ag Composition for treatment of cxcl8-mediated lung inflammation
SMT202000095T1 (it) 2010-05-14 2020-03-13 Amgen Inc Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
IT1406201B1 (it) 2010-12-10 2014-02-14 Univ Degli Studi Trieste Biomarcatori per la diagnosi della sclerosi multipla
CA2826820A1 (en) 2011-03-11 2012-09-20 F. Hoffmann-La Roche Ag Asc as marker for chronic obstructive pulmonary disease (copd)
JP6170071B2 (ja) 2012-02-06 2017-07-26 ユニバーシティ オブ マイアミ Ｃｎｓ損傷についてのバイオマーカーとしての自然免疫タンパク質
TWI480044B (zh) 2012-03-16 2015-04-11 Taichung Veterans General Hospital A high molecular weight heparin or low molecular weight heparin for the preparation of a composition for at least two consecutive days of administration to improve the allergic constitution
US20140314746A1 (en) * 2013-03-13 2014-10-23 Philadelphia Health And Education Corporation, d/b/a Drexel University College of Medicine Methods for treating or preventing fibrosis in subjects afflicted with scleroderma
BR112015028338A2 (pt) * 2013-05-17 2017-07-25 Genentech Inc métodos de diagnóstico ou de auxílio no diagnóstico e de tratamento da doença inflamatória intestinal
JP6359013B2 (ja) * 2013-07-29 2018-07-18 国立大学法人 鹿児島大学 １，５−ｄ−アンヒドロフルクトースを含むアポトーシス関連スペック様カード蛋白質の機能阻害薬
AU2015204558B2 (en) * 2014-01-10 2020-04-30 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
US10143709B2 (en) * 2014-05-06 2018-12-04 Indiana University Research And Technology Corporation Use of ASC and ASC-CM to treat ARDS, SARS, and MERS
US10261098B2 (en) 2014-08-18 2019-04-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Biomarkers for diagnosis and management of neuro-immunological diseases
US20160263183A1 (en) 2015-03-10 2016-09-15 Brown University Methods for treating lung disease
CN107531752B (zh) * 2015-05-12 2022-05-10 加利福尼亚大学董事会 用于炎症和纤维化的肽治疗
BR112018003212A2 (pt) 2015-08-17 2018-09-25 Twi Biotechnology Inc diacereína ou seus análogos para inibir a expressão de asc, expressão de nlrp3 e / ou formação de complexo inflamassoma nlrp3
KR101948048B1 (ko) 2016-12-08 2019-02-14 한양대학교 에리카산학협력단 톡소포자충 ｇｒａ７ 항원 유래 재조합 단백질을 유효성분으로 포함하는 결핵 예방 또는 치료용 약학 조성물
US20190336598A1 (en) * 2016-12-29 2019-11-07 University Of Miami Methods for modulating inflammasome activity and inflammation in the lung
CN111356924A (zh) 2017-09-20 2020-06-30 迈阿密大学 检测作为神经障碍生物标记的炎性体蛋白的方法
KR20210071944A (ko) 2018-07-03 2021-06-16 더 유니버시티 오브 마이애미 인플라마솜 관련 질환 또는 상태 치료용 조성물 및 방법

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
INFLAMMATION, vol. 37, JPN6021051350, 2014, pages 924 - 932, ISSN: 0004823448 *
JOURNAL OF IMMUNOLOGY, vol. 184, JPN6021051346, 2010, pages 5819 - 5826, ISSN: 0004823446 *
JOURNAL OF NEUROCHEMISTRY, vol. 136(Suppl.1), JPN6021051351, 2015, pages 29 - 38, ISSN: 0004823449 *
JOURNAL OF TRAUMA AND ACUTE CARE SURGERY, vol. 80, JPN6021051348, March 2016 (2016-03-01), pages 381 - 389, ISSN: 0004823447 *
NEUROCRIT CARE, vol. 11, JPN6021051344, 2009, pages 417 - 426, ISSN: 0004823445 *
SPINAL CORD, vol. 54, JPN6021051341, April 2016 (2016-04-01), pages 951 - 956, ISSN: 0004823443 *
TRANSLATIONAL RESEARCH, vol. 167, JPN6021051343, January 2016 (2016-01-01), pages 35 - 45, ISSN: 0004823444 *

Also Published As

Publication number Publication date
EP3562506A1 (en) 2019-11-06
US20190336598A1 (en) 2019-11-07
WO2021217004A2 (en) 2021-10-28
BR112019013463A2 (pt) 2020-01-07
EP4139348A2 (en) 2023-03-01
RU2019123160A (ru) 2021-01-29
MX2019007916A (es) 2019-12-05
RU2019123160A3 (cg-RX-API-DMAC7.html) 2021-01-29
US20190002550A1 (en) 2019-01-03
KR20200013630A (ko) 2020-02-07
US20200347124A1 (en) 2020-11-05
CA3176518A1 (en) 2021-10-28
WO2021217004A3 (en) 2021-12-16
US20200308262A1 (en) 2020-10-01
EP4139348A4 (en) 2024-08-14
IL267685A (en) 2019-08-29
US11174307B2 (en) 2021-11-16
WO2018126009A1 (en) 2018-07-05
CO2019008087A2 (es) 2019-10-21
EP3562506A4 (en) 2021-01-06
JP2023016835A (ja) 2023-02-02
CA3048864A1 (en) 2018-07-05
SG10202106385XA (en) 2021-07-29
US10961306B2 (en) 2021-03-30
AU2017386550A1 (en) 2019-08-08
PH12019501549A1 (en) 2020-02-24
CN110461356A (zh) 2019-11-15
JP2023515271A (ja) 2023-04-12
US20210324065A1 (en) 2021-10-21
US10703811B2 (en) 2020-07-07
ZA201904861B (en) 2024-11-27

Similar Documents

Publication Publication Date Title
JP2023016835A (ja) 肺におけるインフラマソーム活性及び炎症をモジュレートする方法
CN113316588B (zh) 用于治疗炎性小体相关疾病或病症的组合物和方法
JP6395606B2 (ja) 血液脳関門透過性の調節のためのセマフォリン−４ｄ結合分子の使用
CN1997385B (zh) 膜联蛋白v用于预防动脉血栓和斑块破裂
Li et al. Inhibition of the receptor for advanced glycation end-products (RAGE) attenuates neuroinflammation while sensitizing cortical neurons towards death in experimental subarachnoid hemorrhage
US11840565B2 (en) Methods and compositions for treating virus-associated inflammation
US20230238030A1 (en) Methods for modulating inflammasome activity and inflammation in the lung
HK40016017A (en) Method for modulating inflammasome activity and inflammation in the lung
US20240124570A1 (en) Inflammasome antibody compositon and method for treating neurologic disorder
JP2025530202A (ja) 神経疾患を治療するためのインフラマソーム抗体組成物及び方法
HK40055003A (zh) 用於治疗炎性小体相关疾病或病症的组合物和方法
US20190209680A1 (en) Treatment of acute liver failure
NZ755639A (en) Method for modulating inflammasome activity and inflammation in the lung

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201223

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201223

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211224

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220303

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220523

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220624

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220712